Making glioblastoma treatments more effective
Project 2: Overcoming drug-induced resistance to intrinsic apoptosis in glioblastoma
This research aims to find new ways to make current glioblastoma treatments work better by overcoming how cancer cells resist dying.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11164741 on NIH RePORTER |
What this research studies
Glioblastoma is a very aggressive cancer where current treatments often struggle to kill enough tumor cells. Researchers have found that glioblastoma cells have two specific 'blocks' that help them survive and resist therapies like radiation, chemotherapy, or targeted drugs. While some treatments can remove one of these blocks, the other often remains, allowing the cancer cells to persist. This project focuses on targeting the remaining block, called BCL-xL, in combination with existing therapies to make them much more powerful against glioblastoma.
Who could benefit from this research
Good fit: This research is most relevant for patients diagnosed with glioblastoma, particularly those whose tumors exhibit specific resistance mechanisms to current treatments.
Not a fit: Patients without glioblastoma or those whose tumors do not show the specific resistance pathways being targeted may not directly benefit from this particular approach.
Why it matters
Potential benefit: If successful, this work could lead to new treatment strategies that significantly improve the effectiveness of therapies for glioblastoma patients.
How similar studies have performed: This project builds upon exciting new preliminary data and complementary findings from previous funding, suggesting a promising direction for overcoming treatment resistance.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Nathanson, David a. — University of California Los Angeles
- Study coordinator: Nathanson, David a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.